!!Projects per year
Resumen
Ten new thiosemicarbazone derivatives, furan-2-carbaldehyde thiosemicarbazone (1), 3-methyl-furan-2-carbaldehyde thiosemicarbazone (2), 5-hydroxymethyl-furan-2-carbaldehyde thiosemicarbazone (3), 5-trifuoromethyl-furan-2-carbaldehyde thiosemicarbazone (4), 5-nitro-furan-2-carbaldehyde thiosemicarbazone (5), 5-phenyl-furan-2-carbaldehyde thiosemicarbazone (6), 5-(2-fuorophenyl)-furan-2-carbaldehyde thiosemicarbazone (7), 5-(4-methoxyphenyl)-furan-2-carbaldehyde thiosemicarbazone (8), 5-(1-naphthyl)-furan-2-carbaldehyde thiosemicarbazone (9), and 5-(1H-Pyrazol-5-yl)-furan-2-carbaldehyde
thiosemicarbazone (10) were synthesized by condensing thiosemicarbazide with the respective furan-2-carbaldehyde in methanol.
The prepared compounds were characterized by spectroscopic studies (FT-IR and NMR) and electrospray mass spectrometry. The molecular structures of 2, 6, 7, and 8 have also been determined by X-ray crystallography. Compounds 2, 6, and 7 crystallize in the E conformation about the N1-C6, N1-C11, and N1-C11 bonds, respectively, while 8 adopts the Z conformation about the N1-C12
bond with the presence of an intramolecular N2-H. . .O2 hydrogen bond. All prepared thiosemicarbazone derivatives were evaluated for their in vitro antibacterial, antifungal, and antitumor activities against Staphylococcus aureus strains, Candida albicans/Candida tropicalis fungi, and seven human tumor cell lines (HuTu80, H460, DU145, M-14, HT-29, MCF-7, and LNCaP), respectively. Te antioxidant activity was also studied by the DPPH assay. Compound 5 exhibited signifcant antibacterial activity against Staphylococcus aureus ATCC700699 (MIC = 1 μg/mL) compared to the nitrofurantoin and gentamicin reference drugs
(MIC = 1–25 and 10->100 μg/mL, respectively). Compound 4 was ten times less active than amphotericin B (MIC = 5 μg/mL) against Candida albicans ATCC90028 and ATCC10231), while 1 exhibited a moderate efect of scavenging of DPPH radical (IC50 = 40.9 μg/mL) in comparison to ascorbic acid reference compound (IC50 = 22.0 μg/mL). Among all the studied thiosemicarbazones, 5 showed a higher cytotoxic activity (IC50 = 13.36–27.73 μΜ) in relation to the other tested compounds (IC50 = 34.84—>372.34 μΜ) against all tested cell lines, except the LNCaP cell line, exhibiting its highest antiproliferative activity
(IC50 = 13.36 μΜ) on the HuTu80 cell line. Besides, 8 and 9 exhibited high antitumor activity (IC50 = 13.31 and 7.69 μΜ, respectively) against the LNCaP cells.
thiosemicarbazone (10) were synthesized by condensing thiosemicarbazide with the respective furan-2-carbaldehyde in methanol.
The prepared compounds were characterized by spectroscopic studies (FT-IR and NMR) and electrospray mass spectrometry. The molecular structures of 2, 6, 7, and 8 have also been determined by X-ray crystallography. Compounds 2, 6, and 7 crystallize in the E conformation about the N1-C6, N1-C11, and N1-C11 bonds, respectively, while 8 adopts the Z conformation about the N1-C12
bond with the presence of an intramolecular N2-H. . .O2 hydrogen bond. All prepared thiosemicarbazone derivatives were evaluated for their in vitro antibacterial, antifungal, and antitumor activities against Staphylococcus aureus strains, Candida albicans/Candida tropicalis fungi, and seven human tumor cell lines (HuTu80, H460, DU145, M-14, HT-29, MCF-7, and LNCaP), respectively. Te antioxidant activity was also studied by the DPPH assay. Compound 5 exhibited signifcant antibacterial activity against Staphylococcus aureus ATCC700699 (MIC = 1 μg/mL) compared to the nitrofurantoin and gentamicin reference drugs
(MIC = 1–25 and 10->100 μg/mL, respectively). Compound 4 was ten times less active than amphotericin B (MIC = 5 μg/mL) against Candida albicans ATCC90028 and ATCC10231), while 1 exhibited a moderate efect of scavenging of DPPH radical (IC50 = 40.9 μg/mL) in comparison to ascorbic acid reference compound (IC50 = 22.0 μg/mL). Among all the studied thiosemicarbazones, 5 showed a higher cytotoxic activity (IC50 = 13.36–27.73 μΜ) in relation to the other tested compounds (IC50 = 34.84—>372.34 μΜ) against all tested cell lines, except the LNCaP cell line, exhibiting its highest antiproliferative activity
(IC50 = 13.36 μΜ) on the HuTu80 cell line. Besides, 8 and 9 exhibited high antitumor activity (IC50 = 13.31 and 7.69 μΜ, respectively) against the LNCaP cells.
| Título traducido de la contribución | Nuevos derivados tiosemicarbazonas a partir del furano-2-carbaldehído: Síntesis, caracterización, estructuras cristalinas y actividades antibacterial, antifungi, antioxidante y antitumoral |
|---|---|
| Idioma original | Inglés |
| Número de artículo | Article ID 5413236 |
| Número de páginas | 20 |
| Publicación | journal of chemistry |
| Volumen | 2023 |
| N.º | ID 5413236 |
| Fecha en línea anticipada | 14 set. 2023 |
| Estado | Publicada - 14 set. 2023 |
Proyectos
- 2 Terminado
-
QMI: Nuevos complejos de platino(II) y paladio(II) con derivados del furano-2-carbaldehído tiosemicarbazona y su actividad antitumoral
Hernández Gorritti, W. R. (Investigador principal), Carrasco Solis, F. C. (Investigador adjunto), Vaisberg, A. J. (Investigador adjunto), Spodine, E. (Investigador adjunto), Icker, M. (Investigador adjunto), Krautscheid, H. (Investigador adjunto) & Beyer, L. (Investigador adjunto)
1/04/21 → 31/03/22
Proyecto: Investigación
-
Nuevos complejos de platino(II) con derivados del tiofeno-2-carbaldehído tiosemicarbazona y sus actividades antibacteriana y antitumoral
Hernández Gorritti, W. R. (Investigador principal) & Carrasco Solis, F. C. (Investigador adjunto)
1/04/19 → 31/03/20
Proyecto: Investigación
Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver